Pira1 Inhibitors
Pira1 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the enzyme known as Pira1. This enzyme, which is encoded by the PIR1 (phosphoinositide-reactive phosphatase 1) gene, is involved in a cellular process that is crucial for the proper functioning of various biological pathways. The inhibition of Pira1 by these compounds results in the modulation of the enzyme's activity, which can lead to alterations in cellular signaling and function. The design of Pira1 inhibitors is based on the precise understanding of the enzyme's structure and the biochemical mechanisms it employs to act on its substrates. These inhibitors typically work by binding to the active site of the enzyme, or to allosteric sites that can induce conformational changes in the enzyme structure, thus preventing the enzyme from interacting with its substrates.
The development of Pira1 inhibitors involves sophisticated techniques such as high-throughput screening, molecular docking, and structure-activity relationship (SAR) studies. These methods are employed to identify potential inhibitory compounds that possess high specificity and affinity for the Pira1 enzyme. Once identified, these compounds are often optimized through a series of chemical modifications to enhance their efficacy, selectivity, and stability. The structure of Pira1 includes a catalytic domain that is typically targeted by these inhibitors, which may mimic the substrate or transition state of the enzymatic reaction, thereby blocking the enzyme's catalytic activity. The study of Pira1 inhibitors is a dynamic field that involves organic chemistry, medicinal chemistry, and computational chemistry to explore and develop new compounds that can effectively modulate the function of the Pira1 enzyme.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of Mitogen-activated protein kinase kinase (MEK), which subsequently reduces the activity of the MAPK/ERK pathway. The inhibition of this pathway can lead to decreased phosphorylation and activation of various downstream targets, including Pira1, if Pira1 is a substrate or is regulated by the MAPK/ERK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of the phosphoinositide 3-kinases (PI3K) pathway. By inhibiting PI3K, LY294002 prevents the activation of Akt, which could be upstream of Pira1, thus leading to its functional inhibition by reducing the signaling that may be necessary for Pira1 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in inflammatory responses and stress-induced signaling. Inhibition of p38 MAPK can affect the phosphorylation state of proteins downstream or within the same signaling cascade as Pira1, potentially reducing Pira1 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). The ROCK pathway is implicated in various cellular functions including contraction, motility, and proliferation. Inhibition of ROCK can alter the cellular environment and signaling pathways that could indirectly inhibit Pira1 if it is functionally linked to these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which impacts cellular stress and cytokine response pathways. By inhibiting JNK, SP600125 could decrease the functional activity of Pira1 if Pira1 is involved in JNK-mediated signaling or regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits both MEK1 and MEK2, preventing the activation of ERK1/2 in the MAPK pathway. This blockade lowers the activity of downstream effector proteins and transcription factors that could be involved in the regulation of Pira1 expression or activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, similar to LY294002. It prevents the phosphorylation and activation of Akt and downstream signaling pathways, which could lead to the inhibition of Pira1 if it is dependent on PI3K/Akt signaling for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is critical for cell growth and proliferation. If Pira1 activity is linked to mTOR signaling, the inhibition of mTOR by rapamycin could lead to a decrease in Pira1 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, c-KIT, and PDGF receptors. If Pira1 activity is associated with tyrosine kinase signaling, imatinib could indirectly inhibit the functional activity of Pira1 by blocking the necessary tyrosine phosphorylation events. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. It alters chromatin structure and affects gene expression. If the expression or activity of Pira1 is modulated by HDACs, its inhibition could lead to decreased Pira1 activity. | ||||||